Rensselaer Polytechnic Institute Partners with Icahn School of Medicine at Mount Sinai to Train Tomorrow’s Health Care and Technology Leaders


Contact: Media Relations

December 4, 2013

Rensselaer Polytechnic Institute Partners with Icahn School of Medicine at Mount Sinai to Train Tomorrow’s Health Care and Technology Leaders

New $5 Million Research and Technology Hub at Mount Sinai is Critical Part of New $100 Million Public-Private Partnership to Boost New York City’s Biotechnology and Entrepreneurship Sectors

Rensselaer Polytechnic Institute will strengthen its strategic partnership with the Icahn School of Medicine at Mount Sinai on the launch of the new Mount Sinai Institute of Technology (MSIT).

Announced today as part of a $100 million public-private initiative to boost biotechnology innovation in New York, MSIT aims to educate a new generation of experts and create new technologies to help address and solve the world’s most critical health-care challenges. See the full announcement at:

MSIT is supported by $5 million from the city of New York.

“The Mount Sinai Institute of Technology is a robust extension of our partnership with the Icahn School of Medicine,” said Rensselaer President Shirley Ann Jackson. “This research and technology hub will enable innovation and discovery in biomedical technologies, health-care analytics, and education, and will drive economic development and improved health care. Rensselaer will work closely with Mount Sinai to foster the growth of the MSIT, while expanding opportunities to build Rensselaer-driven biomedical technologies upstate.”

“We are grateful to the New York City Economic Development Corporation and the administration of Mayor Michael R. Bloomberg for their generous support in helping to make MSIT a reality,” said Dennis S. Charney, the Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai and executive vice president for academic affairs at the Mount Sinai Medical Center. “The city has long recognized the need to expand applied science education and to establish research facilities for these efforts. The work that we’ll carry out at the Institute – from basic research to developing medical technology and devising effective treatments – will ultimately go a long way toward helping improve patient outcomes and the quality of life for people in New York City and beyond.”

MSIT seeks to transform biomedicine through discovery and development of technology-based solutions to critical unmet health-care needs. Students and faculty will engage in academic research, product development, and active entrepreneurship in areas including Big Data, cloud computing, social networking, scientific and clinical simulation, tissue engineering, sensors, microprocessors, robotics, mechatronics, drug delivery and nanomedicine, and other areas, ultimately conferring graduate degrees in Design, Technology, and Entrepreneurship (Ph.D.) and Biomedical Informatics (M.S.).

As part of the MSIT program, which will begin in the fall of 2014, Rensselaer and Mount Sinai will collaborate on the creation of five multidisciplinary research teams. Comprised of faculty members, post-doctoral scholars, and students from both institutions, each team will be devoted to solving a specific technology problem.

This collaboration furthers the partnership between Rensselaer and Mount Sinai, which in May 2013  announced an affiliation agreement to collaborate on educational programs, research, and development of new diagnostic tools and treatments that promote human health. The affiliation leverages the expertise of Rensselaer in engineering and invention prototyping and the expertise of Mount Sinai in biomedical research and patient care to develop joint educational programs, create complementary research programs, and to seek joint research funding.

The affiliation expands the research conducted at both institutions in the areas of neuroscience and neurological diseases, genomics, imaging, orthopaedics, cancer, cardiovascular disease, and scientific and clinical targets. Funding for projects will be sought on topics including precision medicine, drug discovery, stem cell biology, robotics and robotic surgery, novel imaging techniques, cellular engineering, and computational neurobiology.

Big Data, broad data, high performance computing, data analytics, and Web science are creating a significant transformation globally in the way we make connections, make discoveries, make decisions, make products, and, ultimately, make progress. The collaboration with Mount Sinai on MSIT, under the auspices of the Rensselaer Institute for Data Exploration and Applications – or The Rensselaer IDEA, is part of the university-wide effort at Rensselaer to maximize the capabilities of these tools and technologies for the purpose of expediting scientific discovery and innovation, developing the next generation of these digital enablers, and preparing our students to succeed and lead in this new data-driven world.

For more on the alliance between Rensselaer and Mount Sinai, see:


For general inquiries:

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, over 30 research centers, more than 140 academic programs including 25 new programs, and a dynamic community made up of over 6,800 students and 104,000 living alumni. Rensselaer faculty and alumni include upwards of 155 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit